Benzinga | Dec 7, 2020 06:59AM EST

Wells Fargo Downgrades CRISPR Therapeutics to Equal-Weight, Announces $145 Price Target

Wells Fargo analyst Jim Birchenough downgrades CRISPR Therapeutics (NASDAQ:CRSP) from Overweight to Equal-Weight and announces $145 price target.